AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 44(4), 1991, pp. 394-398
Copyright © 1991 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saenz, R. E.
Right arrow Articles by Berman, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saenz, R. E.
Right arrow Articles by Berman, J. D.

Efficacy and Toxicity of Pentostam against Panamanian Mucosal Leishmaniasis

R. E. Saenz, C. G. de Rodriguez, C. M. Johnson AND J. D. Berman
Gorgas Memorial Laboratory, Panama City, Panama; Santos Hospital, Panama City, Panama; Walter Reed Army Institute of Research, Washington, DC

We tested the World Health Organization (WHO) recommended treatment for mucosal leishmaniasis in 16 Panamanians with disease due to Leishmania braziliensis panamensis. Disease was mild in this population because it was limited to the nasal mucosa and only one patient had septal perforation. The patients were administered 20 mg antimony (in the form of Pentostam) per kg intravenously each day for 28 days. Ten patients completed therapy and were cured at 12 month follow-up. Three patients completed therapy, healed their lesions, but relapsed at the six or 12 month follow-up. Three patients terminated therapy prematurely because of liver enzyme elevations in conjunction with either EKG abnormalities or musculoskeletel complaints; none of these patients were healed. This study indicates that in patients with mild mucosal leishmaniasis, the WHO regimen is curative in 77% patients who complete treatment and in 63% of all patients.




This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
V. S. Amato, F. F. Tuon, A. M. Siqueira, A. C. Nicodemo, and V. A. Neto
Treatment of Mucosal Leishmaniasis in Latin America: Systematic Review
Am J Trop Med Hyg, August 1, 2007; 77(2): 266 - 274.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. F. Weller, M. L. Durand, and B. Z. Pilch
Case 4-2005 - A 35-Year-Old Man with Nasal Congestion, Swelling, and Pain
N. Engl. J. Med., February 10, 2005; 352(6): 609 - 615.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Society of Tropical Medicine and Hygiene.